1. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Issue 3 (June 2016) Authors: Thomas, Katja; Eisele, Judith; Rodriguez-Leal, Francisco Alejandro; Hainke, Undine; Ziemssen, Tjalf Journal: Neurology Issue: Volume 3:Issue 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. (October 2017) Authors: Ziemssen, Tjalf; Thomas, Katja Journal: Therapeutic advances in neurological disorders Issue: Volume 10:Number 10(2017) Page Start: 343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?. (September 2018) Authors: Rodriguez-Leal, Francisco Alejandro; Haase, Rocco; Thomas, Katja; Eisele, Judith Christina; Proschmann, Undine; Schultheiss, Thorsten; Kern, Raimar; Ziemssen, Tjalf Journal: Multiple sclerosis Issue: Volume 24:Number 10(2018) Page Start: 1337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. (13th October 2017) Authors: Thomas, Katja; Proschmann, Undine; Ziemssen, Tjalf Journal: Expert opinion on pharmacotherapy Issue: Volume 18:Number 15(2017) Page Start: 1649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Issue 1 (December 2016) Authors: Hassoun, Lina; Eisele, Judith; Thomas, Katja; Ziemssen, Tjalf Journal: Multiple sclerosis and demyelinating disorders Issue: Volume 1:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Laquinimod in the treatment of relapsing remitting multiple sclerosis. (2nd June 2016) Authors: Hainke, Undine; Thomas, Katja; Ziemssen, Tjalf Journal: Expert opinion on drug metabolism and toxicology Issue: Volume 12:Number 6(2016:Jun.) Page Start: 701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing". (May 2018) Authors: Sehr, Tony; Proschmann, Undine; Thomas, Katja; Ziemssen, Tjalf Journal: Multiple sclerosis Issue: Volume 24:Number 6(2018) Page Start: 820 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. Issue 1 (December 2016) Authors: Ziemssen, Tjalf; Kern, Raimar; Thomas, Katja Journal: BMC neurology Issue: Volume 16:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Natalizumab during pregnancy and lactation. (October 2018) Authors: Proschmann, Undine; Thomas, Katja; Thiel, Sandra; Hellwig, Kerstin; Ziemssen, Tjalf Journal: Multiple sclerosis Issue: Volume 24:Number 12(2018) Page Start: 1627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS). Issue 1 (December 2016) Authors: Ziemssen, Tjalf; Engelmann, Ulrich; Jahn, Sigbert; Leptich, Alexandra; Kern, Raimar; Hassoun, Lina; Thomas, Katja Journal: BMC neurology Issue: Volume 16:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗